The global cell and gene therapy market, valued at USD 17.40 Billion in 2024, is witnessing rapid expansion due to strong regulatory support and rising clinical trials across the world. With the growing adoption of personalized medicine and breakthroughs in genetic science, the market is expected to rise at a CAGR of 23.17% from 2025 to 2034, ultimately reaching USD 139.83 Billion by 2034.Market Overview
Cell and gene therapies are transforming modern healthcare by offering long-term, and in many cases, potentially curative treatments for chronic, rare, and previously untreatable conditions. The integration of advanced genetic tools, including CRISPR, viral vectors, and regenerative platforms, has significantly accelerated therapeutic development and regulatory approvals.
The demand for innovative treatments for cancer, rare genetic disorders, muscular dystrophies, and autoimmune diseases continues to surge. This demand, combined with growing biotech investments, is boosting global market value at an unprecedented pace.
Key Market Drivers
Rising global clinical trials: Thousands of active CGT trials are in progress, strengthening the commercial pipeline.
Strong regulatory backing: Accelerated pathways like RMAT and orphan drug designations are supporting rapid market entry.
Technological advancements: Innovations in gene editing, stem cell therapies, and viral vector manufacturing enhance efficiency and scalability.
Growing investment in advanced therapeutics: Biopharma companies and CDMOs are expanding manufacturing capacity to meet increasing demand.
Market Challenges
While the market outlook is strong, certain barriers persist:
High therapy and manufacturing costs
Complex regulatory processes
Limited skilled workforce for biologics and cell manipulation
Despite these challenges, continued R&D and cost-efficient production strategies are expected to streamline future growth.
Get a Free Sample Report with Table of Contents - www.expertmarketresearch.com/reports/cell-and-gene-therapy-cgt-market/requestsample
Competitive Landscape
Major companies driving the global cell and gene therapy market include:
Amgen Inc., Novartis AG, Pfizer Inc., Bluebird Bio Inc., Castle Creek Pharmaceutical Holdings, Bristol-Myers Squibb, Kite Pharma Inc., Vericel Corporation Inc., Kolon TissueGene Inc., Vertex Pharmaceuticals Inc., Spark Therapeutics Inc., CORESTEM Inc., Biogen Inc., Dendreon Pharmaceuticals LLC, and JCR Pharmaceuticals Co. Ltd.
These companies are heavily investing in CAR-T therapies, regenerative platforms, gene-based treatments, and advanced clinical research, contributing significantly to market expansion.Cell and Gene Therapy Market